Technical Analysis for TH - Theratechnologies Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.700 | 0.00% | 0.000 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Inside Day | Range Contraction | 1.19% | |
| Gapped Down | Weakness | 1.19% | |
| 50 DMA Resistance | Bearish | -0.58% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 2 hours ago |
| Gap Up Partially Closed | about 2 hours ago |
| Reversed from Up | about 2 hours ago |
| Gapped Up (Partial) | about 3 hours ago |
| Shooting Star Candlestick Entry | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 2024-10-10
Theratechnologies Inc. Description
Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Drug Medical Specialties IPO Organ Systems Infection Hiv Immunology Rift Antivirals
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.43 |
| 52 Week Low | 1.59 |
| Average Volume | 39,655 |
| 200-Day Moving Average | 1.838 |
| 50-Day Moving Average | 1.722 |
| 20-Day Moving Average | 1.728 |
| 10-Day Moving Average | 1.728 |
| Average True Range | 0.075 |
| RSI (14) | 47.09 |
| ADX | 16.08 |
| +DI | 25.600 |
| -DI | 16.702 |
| Chandelier Exit (Long, 3 ATRs) | 1.675 |
| Chandelier Exit (Short, 3 ATRs) | 1.855 |
| Upper Bollinger Bands | 1.811 |
| Lower Bollinger Band | 1.645 |
| Percent B (%b) | 0.33 |
| BandWidth | 9.641 |
| MACD Line | -0.011 |
| MACD Signal Line | -0.002 |
| MACD Histogram | -0.0082 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.775 | ||||
| Resistance 3 (R3) | 1.780 | 1.760 | 1.763 | ||
| Resistance 2 (R2) | 1.760 | 1.741 | 1.758 | 1.758 | |
| Resistance 1 (R1) | 1.730 | 1.729 | 1.725 | 1.725 | 1.754 |
| Pivot Point | 1.710 | 1.710 | 1.708 | 1.708 | 1.710 |
| Support 1 (S1) | 1.680 | 1.691 | 1.675 | 1.675 | 1.646 |
| Support 2 (S2) | 1.660 | 1.679 | 1.658 | 1.642 | |
| Support 3 (S3) | 1.630 | 1.660 | 1.638 | ||
| Support 4 (S4) | 1.625 |
